Literature DB >> 2996148

Biological heterogeneity of small cell lung cancer.

D N Carney, A F Gazdar, M Nau, J D Minna.   

Abstract

Over the past 20 years considerable advances have been made in the characterization of the biologic properties of small cell lung cancer. The recognition that this histologic type of lung cancer, in contrast to the other major types of lung cancer, is highly sensitive to both chemotherapy and radiation therapy lead to significant improvements in the overall survival of patients with this disease. However, in spite of the initial major advances in therapy, overall results and survival have remained unchanged over the past 5 years. The majority of patients, although they will demonstrate an initial response to cytotoxic therapy, will ultimately die of their disease due to the development of drug resistance. Whether this development of drug resistance within a tumor cell represents the emergence of resistant clones of cells present at diagnosis, or a change within the cells exposed to cytotoxic therapy that renders them resistant to further therapy remains to be determined. The development of laboratory techniques that facilitate the culture and establishment of SCLC cell lines has greatly improved our understanding of the biology of SCLC, in addition to providing useful models for studies of mechanisms of drug resistance and metabolism. The ease of establishment of SCLC cell lines in defined medium suggests that these cells secrete "autocrine growth factors" essential for their growth in vitro. The characterization of these factors may provide an alternative means for treating this tumor in vivo. Moreover, by developing specific culture media for other types of lung cancer, similar advances in our knowledge of these tumors will occur. Although the growth of SCLC cells in a clonogenic assay may be of value in chemotherapy selection, the established cell lines provide a model for studying mechanisms of drug and radiation sensitivity; and drug metabolism. The recognition that SCLC cell lines have elevated levels of L-dopa decarboxylase has lead to the development of specific agents that may alter the growth of these cells through inhibition of polyamine synthesis. Such specifically designed therapy may become important in the future therapy of these patients. The establishment of cell lines has clearly indicated the considerable heterogeneity that exists in SCLC.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2996148

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  11 in total

1.  Immunotargeting of human small cell lung cancer xenografts in athymic mice using a monoclonal antibody (RNL-1) against a neuroendocrine-related antigen.

Authors:  E P Mijnheere; O C Boerman; J L Broers; M Klein Rot; G P Vooijs; F C Ramaekers
Journal:  Br J Cancer Suppl       Date:  1991-06

2.  Small cell carcinoma of the bronchus: historical perspective of a treatable disease.

Authors:  S W Watkin; J A Green
Journal:  J R Soc Med       Date:  1990-02       Impact factor: 5.344

3.  The role of ifosfamide and cyclophosphamide in the multi-modality treatment after surgery for cure for small-cell bronchial carcinomas (SCLC).

Authors:  K Karrer; H Denck; H Karnicka-Mlodkowska; P Drings; J Orel; G M Salzer; M Thermann; A Lattuneddu; Y Sun; E Hata
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

4.  Tetanus toxin as a marker for small-cell lung cancer cell lines.

Authors:  J Heymanns; K Neumann; K Havemann
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

5.  Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes.

Authors:  Wei Zhang; Luc Girard; Yu-An Zhang; Tomohiro Haruki; Mahboubeh Papari-Zareei; Victor Stastny; Hans K Ghayee; Karel Pacak; Trudy G Oliver; John D Minna; Adi F Gazdar
Journal:  Transl Lung Cancer Res       Date:  2018-02

6.  A high molecular weight non-bombesin/gastrin releasing peptide growth factor in small cell lung cancer.

Authors:  V Macaulay; G P Joshi; M Everard; I E Smith; J L Millar
Journal:  Br J Cancer       Date:  1987-12       Impact factor: 7.640

7.  Alternative implication of CXCR4 in JAK2/STAT3 activation in small cell lung cancer.

Authors:  M Pfeiffer; T N Hartmann; M Leick; J Catusse; A Schmitt-Graeff; M Burger
Journal:  Br J Cancer       Date:  2009-05-19       Impact factor: 7.640

8.  In vitro effects of substance P analogue [D-Arg1, D-Phe5, D-Trp7,9, Leu11] substance P on human tumour and normal cell growth.

Authors:  M J Everard; V M Macaulay; J L Miller; I E Smith
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

9.  Integrated glycoproteomics demonstrates fucosylated serum paraoxonase 1 alterations in small cell lung cancer.

Authors:  Jung-Mo Ahn; Hye-Jin Sung; Yeon-Hee Yoon; Byung-Gyu Kim; Won Suk Yang; Cheolju Lee; Hae-Min Park; Bum-Jin Kim; Byung-Gee Kim; Soo-Youn Lee; Hyun-Joo An; Je-Yoel Cho
Journal:  Mol Cell Proteomics       Date:  2013-10-01       Impact factor: 5.911

10.  miR-93-directed downregulation of DAB2 defines a novel oncogenic pathway in lung cancer.

Authors:  L Du; Z Zhao; X Ma; T-H Hsiao; Y Chen; E Young; M Suraokar; I Wistuba; J D Minna; A Pertsemlidis
Journal:  Oncogene       Date:  2013-09-16       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.